Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

headcount, reduction, revenue per employee

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.  Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025…

Mar 23^rd • 10 mins read

The Great Resignation is Now The Great Hesitation

careers

Over the last few years, the employment market has moved through dramatic swings. In 2021 and 2022, millions of professionals left their roles in what became known as The Great Resignation. Jobs were abundant, companies were aggressively hiring, and the perceived level of risk was low. If a new role…

Nov 19^th • 5 mins read

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

patient engagement in pharma, patient-centric drug development, life sciences industry innovation, patient insights in medicine, regulatory compliance in patient engagement, patient involvement in clinical trials, benefits of patient advocacy, patient-cen

The life sciences industry is in a constant state of advancement, bringing more and more groundbreaking medicines, cutting-edge technologies, and innovative solutions to market. Amidst these rapid changes, patients remain at the heart of these scientific developments. In recent decades, the l…

May 9^th • 5 mins read

The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years

inclusion, woman, global, oncology drug trials, NIH

Women represented 77% of newly diagnosed thyroid cancer cases in 2020 but only comprised 51% of participants in related trials. Women accounted for 48% of global colon cancer cases but only 33% of trial participants for colon cancer therapeutics. Higher enrollment of women in NIH-funded studies …

Aug 26^th • 2 mins read